Meridian Wealth Partners’s Sage Therapeutics SAGE Stock Holding History

Meridian Wealth Partners’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4	Closed	–	–	1026
2021 Q1	$0	Buy	+4	New	+$328	﹤0.01%	1439

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Meridian Wealth Partners's SAGE Position: Q2 2021 in Review

Meridian Wealth Partners sold out of Sage Therapeutics (SAGE) in Q2 2021, closing a stake of 4 shares.

Meridian Wealth Partners first reported a position in SAGE in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 256 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

Meridian Wealth Partners reported no remaining Sage Therapeutics position as of Q2 2021 after selling out during the quarter.
Meridian Wealth Partners sold 4 Sage Therapeutics shares in Q2 2021.
Meridian Wealth Partners first reported a position in Sage Therapeutics in Q1 2021 and held it in 1 quarter.
Meridian Wealth Partners's Sage Therapeutics position peaked at $0 in Q1 2021.
256 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on Meridian Wealth Partners's 13F filing for Q2 2021, filed 12 Aug 2021.